GlassScriptPhysician profile
Stacey Gruber
NPI 1790948073
$3,654.84
in general payments reported to CMS, 2019-2025
36 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $61.91 · 2021: $199 · 2022: $973 · 2023: $561 · 2024: $761 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $655.08 | 2021-2025 | Austedo Xr, Austedo, Ajovy |
| Abbvie INC. | $628.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $281.18 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $234.69 | 2019-2024 | Ultomiris, Soliris |
| Lilly USA, LLC | $185.75 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Lundbeck LLC | $166.81 | 2021-2025 | Rexulti, Vyepti |
| Amgen INC. | $138.93 | 2022-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $111.48 | 2024-2025 | Ingrezza |
| Biogen, INC. | $106.64 | 2019-2023 | Tysabri, Vumerity |
| Alnylam Pharmaceuticals INC. | $105.64 | 2022-2025 | Onpattro, Givlaari |
| Emd Serono, INC. | $104.79 | 2019-2023 | Mavenclad |
| Ge Healthcare | $70.51 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $68.24 | 2022-2023 | Nuplazid |
| Tanabe Pharma America, INC. | $67.14 | 2024-2025 | Radicava |
| Pfizer INC. | $59.12 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $52.63 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $50.55 | 2024-2025 | Hyqvia |
| Janssen Pharmaceuticals, INC | $48.90 | 2022 | |
| Eisai INC. | $47.98 | 2025 | |
| Ucb, INC. | $46.36 | 2023-2024 | Zilbrysq |
| Argenx US, INC. | $44.97 | 2022 | |
| Neurelis, INC. | $43.70 | 2022-2025 | Valtoco |
| Allergan, INC. | $43.69 | 2019-2022 | |
| Genzyme Corporation | $35.11 | 2022 | |
| Genentech USA, INC. | $31.93 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Acorda Therapeutics, INC | $28.49 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $26.41 | 2021 | |
| Nevro Corp. | $26.20 | 2022 | |
| Celgene Corporation | $25.34 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.10 | 2023 | Andexxa |
| Amneal Pharmaceuticals LLC | $20.01 | 2023 | Rytary |
| Corcept Therapeutics | $17.51 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $15.43 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Csl Behring | $14.71 | 2025 | Hizentra |
| Tg Therapeutics, INC. | $13.21 | 2024 | |
| Boston Scientific Corporation | $13.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Gruber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.